Endo Mizuki, Yazawa Shin, Sano Rie, Yokobori Takehiko, Shirabe Ken, Saeki Hiroshi
Department of General Surgical Science, Graduate School of Medicine, Gunma University, Maebashi 371-8511, Japan.
Department of Legal Medicine, Graduate School of Medicine, Gunma University, Maebashi 371-8511, Japan.
Diagnostics (Basel). 2024 Dec 27;15(1):40. doi: 10.3390/diagnostics15010040.
: Previously, we reported elevated levels of fucosylated α-acid glycoprotein (fAGP) in plasma samples from patients with diverse types of cancers. Accordingly, fAGP was assumed to be a potential biomarker for the early detection of cancers. : The fAGP level was retrospectively measured in preoperative plasma samples from 213 patients with either hepatic, biliary tract, or pancreatic cancer and was analyzed together with levels of six existing tumor markers determined as reference standards. : When the cutoff value was set at 25.45 U/μg, elevated levels of fAGP were significantly observed in cancer patients. The sensitivity, specificity, and accuracy for the detection of malignancy in these diseases were determined to be 70.79, 51.72, and 68.12, respectively. In contrast, all the tumor markers exhibited low sensitivity and accuracy, even though they commonly had extremely high (≥80%) specificity. Further, a significant number of patients in both early and advanced clinical stages were found to be false negative in these tumor makers but were found to be positive in the fAGP level. A dramatic improvement in the diagnosis by tumor markers in such patients with all clinical stages was found by the determination of the fAGP level. This indicated that fAGP could serve to correct false-negative diagnosis with tumor markers. : It is believed that fAGP could be a relevant, unique, and highly sensitive biomarker for early diagnosis of hepatobiliary and pancreatic cancers.
此前，我们报道了来自不同类型癌症患者的血浆样本中岩藻糖基化α-酸性糖蛋白（fAGP）水平升高。因此，fAGP被认为是癌症早期检测的潜在生物标志物。：回顾性测量了213例肝癌、胆管癌或胰腺癌患者术前血浆样本中的fAGP水平，并与作为参考标准测定的六种现有肿瘤标志物水平一起进行分析。：当临界值设定为25.45 U/μg时，在癌症患者中显著观察到fAGP水平升高。这些疾病中检测恶性肿瘤的敏感性、特异性和准确性分别确定为70.79、51.72和68.12。相比之下，所有肿瘤标志物的敏感性和准确性都较低，尽管它们通常具有极高（≥80%）的特异性。此外，在早期和晚期临床阶段的大量患者中，这些肿瘤标志物检测结果为假阴性，但fAGP水平检测结果为阳性。通过测定fAGP水平，发现所有临床阶段此类患者的肿瘤标志物诊断有显著改善。这表明fAGP可用于纠正肿瘤标志物的假阴性诊断。：据信，fAGP可能是肝胆胰癌早期诊断的一种相关、独特且高度敏感的生物标志物。
